PubMed · 1080300
Plasma components which interfere with ristocetin-induced platelet aggregation.
Abstract
Normal human plasma contains a component or components which interfere with ristocetin-induced platelet aggregation. Preliminary examination suggests a protein (or proteins) which binds ristocetin and competes more effectively for ristocetin than do the proteins involved in ristocetin-induced platelet aggregation. The presence of this protein in normal human plasma also prevents ristocetin-induced precipitation of plasma proteins at levels of ristocetin necessary to produce platelet aggregation (0.5-2.0 mg/ml). Serum contains an apparent two0fold increase of this component when compared with plasma. Heating serum at 56 degrees for one hour results in ad additional 2 to 4 forl increase. The presence of a ristocetin-binding protein in normal human plasma requires that this protein be saturated with ristocetin before ristocetin-induced platelet aggregation will occur. Variations in the ristocetin-binding protein(s) will cause apparent discrepancies in ristocetin-induced platelet aggregation in normal human plasmas.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
R F Baugh, J E Brown, C Hougie. 1975-06-30. Plasma components which interfere with ristocetin-induced platelet aggregation.. https://pubmed.ncbi.nlm.nih.gov/1080300/
Cite the original work for its findings. Save a collection to share your selection of sources.